Predictors of anti-vascular endothelial growth factor treatment responses in macular edema following central vein occlusion

Chin Med J (Engl). 2014;127(16):3019-23.

Authors

Peirong Huang¹, Zhengyu Song², Xiaodong Sun³

Affiliations

¹ Department of Ophthalmology, Shanghai First People's Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai 200080, China.
² Shanghai Key Laboratory of Fundus Disease, Eye Research Institute of Shanghai Jiao Tong University, Shanghai 200080, China.
³ Department of Ophthalmology, Shanghai First People's Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai 200080, China. Email: xdsun@sjtu.edu.cn.

PMID: 25131244

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Aptamers, Nucleotide / therapeutic use
Bevacizumab
Humans
Macular Edema / drug therapy*
Ranibizumab
Receptors, Vascular Endothelial Growth Factor / therapeutic use
Recombinant Fusion Proteins / therapeutic use
Retinal Vein Occlusion / drug therapy*
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Visual Acuity / drug effects

Substances

Antibodies, Monoclonal, Humanized
Aptamers, Nucleotide
Recombinant Fusion Proteins
Vascular Endothelial Growth Factor A
aflibercept
pegaptanib
Bevacizumab
Receptors, Vascular Endothelial Growth Factor
Ranibizumab